Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.
Oral orforglipron produced substantially more weight loss than placebo over 72 weeks in Japanese participants, offering a potential new medication option for obesity.
This double-blind randomized placebo-controlled phase 3 trial examined efficacy and safety of oral orforglipron for obesity. At 72 weeks, each orforglipron dose produced substantially more clinically meaningful weight loss than placebo in the randomized trial.
What the study was
- Study design
- Double-blind randomized placebo-controlled phase 3 trial
- Population
- 238 Japanese adults with obesity disease
- Sample size
- 238
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- The lancet. Diabetes & endocrinology
Why it surfaced
Retained as a high-priority double-blind randomized placebo-controlled phase 3 trial after PubMed abstract review; the score reflects clinical relevance, design strength, novelty, and population need under the v1.3 conservative rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.